- $1.67bn
- $1.43bn
- $62.90m
Nuvation Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Nuvation Bio Q2 EPS USD -0.09
Nuvation Bio Inc expected to post a loss of 11 cents a share - Earnings Preview
Nuvation Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Nuvation Bio Reports First Quarter 2023 Financial Results And Provides Business Update
Brief: Nuvation Bio Q4 operating expenses USD 24.335 million
Nuvation Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Nuvation Bio Reports Q4 And Full Year 2022 Financial Results And Provides Business Update
Brief: Nuvation Bio - On Feb 28, Filed Petition In Delaware Court Of Chancery To Resolve Potential Uncertainty With Respect To Co's Authorized Share Capital
Nuvation Bio Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Nuvation Bio Doses First Patient In Phase 1B Combination Study Of Nuv-868
NYSE ORDER IMBALANCE 89540.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 52502.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 61461.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 62706.0 SHARES ON BUY SIDE
U.S. STOCKS ON THE MOVE-Starbucks, J&J, Nikola, Conformis, PayPal
Brief: Nuvation Bio Reports Second Quarter 2022 Financial Results And Provides Business Update
U.S. RESEARCH ROUNDUP-Alight, Stagwell, Transmedics Group
U.S. STOCKS ON THE MOVE-Scynexis, Sierra Wireless, CymaBay